Literature DB >> 34021024

A Comparison of Breathing Stimulants for Reversal of Synthetic Opioid-Induced Respiratory Depression in Conscious Rats.

Kaye E Dandrea1, Joseph F Cotten2.   

Abstract

Potent synthetic opioids are an important cause of death in the United States' opioid epidemic, and a breathing stimulant may have utility in treating opioid overdose. We hypothesized that sufentanil-induced respiratory depression may be reversed by breathing stimulant administration. Using nose-only plethysmography and arterial blood analysis, we compared effects of several breathing stimulants in reversing sufentanil-induced respiratory depression in conscious rats. We studied taltirelin (1 mg/kg i.v.), PKTHPP (5 mg/kg i.v.), CX717 (30 mg/kg i.v.), BIMU8 (1 mg/kg i.v.), A85380 (30 μg/kg i.v.), and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (150 μg/kg i.v./i.m.) and used sufentanil (10 μg/kg i.v.). By plethysmography (in % baseline, mean ± S.E.M.), taltirelin restored ventilation in sufentanil-treated rats (from 50 ± 5% to 102 ± 8%) by increased breathing rates (from 80 ± 4% to 160 ± 12%). By arterial blood analysis, however, taltirelin did not correct hypoxia, decreased hypercarbia only after 45 minutes, and worsened metabolic acidosis (base excess from +0 ± 1 to -7 ± 1 mEq/l). Additionally, taltirelin increased exhaled carbon dioxide, an estimate of oxygen consumption, by up to 64%. PKTHPP, CX717, BIMU8, and A85380 failed to significantly change ventilation or arterial blood values in sufentanil-treated rats. 8-OH-DPAT, however, improved ventilation (from 54 ± 8% to 92 ± 10%), reversed hypercarbia (from 64 ± 6 to 47 ± 2 mmHg), and shortened time to righting from 43 ± 4 to 15 ± 1 minutes in sufentanil-treated rats placed supine. Taltirelin has limited therapeutic potential, as its ventilatory effects are offset by metabolic acidosis, possibly from increased oxygen consumption. At the doses studied, PKTHPP, CX717, BIMU8, and A85380 have limited effects in reversing sufentanil-induced respiratory depression; 8-OH-DPAT, however, warrants further study. SIGNIFICANCE STATEMENT: Respiratory depression is an important cause of death after potent synthetic opioid overdose. 8-Hydroxy-2-(di-n-propylamino)tetralin or related compounds may be useful in treating respiratory depression as caused by potent synthetic opioids.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34021024      PMCID: PMC8686717          DOI: 10.1124/jpet.121.000675

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  39 in total

1.  Hostage deaths put gas weapons in spotlight.

Authors:  Quirin Schiermeier
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

2.  The anatomical basis of the straub phenomenon.

Authors:  D L Bilbey; H Salem; M H Grossman
Journal:  Br J Pharmacol Chemother       Date:  1960-12

3.  Potent, new analgesics, tailor-made for different purposes.

Authors:  P A Janssen
Journal:  Acta Anaesthesiol Scand       Date:  1982-06       Impact factor: 2.105

4.  The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans.

Authors:  B G Oertel; A Schneider; M Rohrbacher; H Schmidt; I Tegeder; G Geisslinger; J Lötsch
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

5.  Activating α4β2 Nicotinic Acetylcholine Receptors Alleviates Fentanyl-induced Respiratory Depression in Rats.

Authors:  Jun Ren; Xiuqing Ding; John J Greer
Journal:  Anesthesiology       Date:  2019-06       Impact factor: 7.892

6.  The counteraction of opioid-induced ventilatory depression by the serotonin 1A-agonist 8-OH-DPAT does not antagonize antinociception in rats in situ and in vivo.

Authors:  Ulf Guenther; Till Manzke; Hermann Wrigge; Matthias Dutschmann; Joerg Zinserling; Christian Putensen; Andreas Hoeft
Journal:  Anesth Analg       Date:  2009-04       Impact factor: 5.108

Review 7.  Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis.

Authors:  Randy Torralva; Aaron Janowsky
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

8.  A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT).

Authors:  Philip Teal; Stephen Davis; Werner Hacke; Markku Kaste; Patrick D Lyden; Monika Fierus
Journal:  Stroke       Date:  2009-09-10       Impact factor: 7.914

9.  Pretreatment with sedative-hypnotics, but not with nondepolarizing muscle relaxants, attenuates alfentanil-induced muscle rigidity.

Authors:  T J Sanford; M B Weinger; N T Smith; J L Benthuysen; N Head; H Silver; T A Blasco
Journal:  J Clin Anesth       Date:  1994 Nov-Dec       Impact factor: 9.452

10.  The potency of different serotonergic agonists in counteracting opioid evoked cardiorespiratory disturbances.

Authors:  M Dutschmann; H Waki; T Manzke; A E Simms; A E Pickering; D W Richter; J F R Paton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-09-12       Impact factor: 6.237

View more
  2 in total

1.  Respiratory effects of thyrotropin-releasing hormone and its analogue taltirelin on opioid-induced respiratory depression.

Authors:  Marijke H Algera; Joseph F Cotten; Monique van Velzen; Marieke Niesters; Martijn Boon; Daniel S Shoham; Kaye E Dandrea; Rutger van der Schrier; Albert Dahan
Journal:  Br J Anaesth       Date:  2022-04-19       Impact factor: 11.719

Review 2.  Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?

Authors:  Marieke Hyke Algera; Joseph F Cotten; Monique van Velzen; Marieke Niesters; Martijn Boon; Daniel S Shoham; Kaye E Dandrea; Rutger van der Schrier; Albert Dahan
Journal:  Pharmacol Res Perspect       Date:  2022-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.